4D Molecular Therapeutics FDMT Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $88.24M+3.6% | $85.21M+70,908% | $120K+264% | $33K+43.5% | $23K-37.8% | ||
| $219.98M+12.4% | $195.7M+8.0% | $181.18M+6.4% | $170.22M+10.4% | $154.13M+9.1% | ||
| $47.81M-2.5% | $49.06M-0.5% | $49.32M-1.6% | $50.14M+1.9% | $49.22M+5.7% | ||
| $267.79M+9.4% | $244.76M+6.2% | $230.5M+4.6% | $220.36M+8.4% | $203.35M+8.2% | ||
| -$194.26M-11.5% | -$174.26M+24.4% | -$230.38M-4.6% | -$220.33M-8.4% | -$203.33M-8.2% | ||
| -220.1%-15.6pp | -204.5%+191,778pp | -191,982.5%+475,672pp | -667,654.5%+216,372pp | -884,026.1%-376,348pp | ||
| $18.65M-4.1% | $19.44M-8.3% | $21.2M-12.3% | $24.18M-10.1% | $26.89M-0.3% | ||
| —— | —— | -$209.18M-6.6% | -$196.14M-11.2% | -$176.44M-9.7% | ||
| —— | —— | -$3.75-6.2% | -$3.53-11.0% | -$3.18-6.7% | ||
| -$189.35M-11.7% | -$169.57M+24.9% | -$225.81M-4.6% | -$215.82M-8.6% | -$198.8M-8.5% | ||
| -214.6%-15.6pp | -199%+187,972pp | -188,170.8%+465,838pp | -654,009.1%+210,317pp | -864,326.1%-369,223pp | ||
| -$194.26M-11.5% | -$174.26M+24.4% | -$230.38M-4.6% | -$220.33M-8.4% | -$203.33M-8.2% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is 4D Molecular Therapeutics's revenue?
- 4D Molecular Therapeutics (FDMT) generated $88.2M in revenue over the trailing twelve months, up 383560.9% year over year.
- Is 4D Molecular Therapeutics profitable?
- 4D Molecular Therapeutics is not currently profitable: it reported a net loss of $228.3M over the trailing twelve months, a -174314.2% net margin.
- What is 4D Molecular Therapeutics's earnings per share?
- 4D Molecular Therapeutics's diluted EPS over the trailing twelve months is $-3.86.
- Where does 4D Molecular Therapeutics's income statement data come from?
- Every line is extracted from 4D Molecular Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
